Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia
2021 · Nature · 1,283 citations
https://doi.org/10.1038/s41586-021-03536-w
M
Mark R. Albertella
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
193
Papers
2.8K
Citations
18
h-index
21
i10-index
Mark R. Albertella is an academic researcher from AstraZeneca (United Kingdom). The author has contributed to research in topics: interferon and immune responses & Cytokine Signaling Pathways and Interactions & Cancer-related molecular mechanisms research. The author has an h-index of 18, co-authored 165 publications.
ORCID: 0000-0003-4406-6135Papers by this author
worksThe PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
2024 · Genome Medicine · 53 citations
https://doi.org/10.1186/s13073-024-01370-z
MALT1 inhibition suppresses antigen-specific T cell responses
2024 · Cellular Immunology · 2 citations
https://doi.org/10.1016/j.cellimm.2024.104814
Figure S1 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunity
2024 · 0 citations
https://doi.org/10.1158/2159-8290.27026081.v1
Figure S3 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunity
2024 · 0 citations
https://doi.org/10.1158/2159-8290.27026075
Figure S7 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunity
2024 · 0 citations
https://doi.org/10.1158/2159-8290.27026063
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat